Lemaitre Vascular (LMAT)
NASDAQ:LMAT
Want to see LMAT full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.81Last Year’s EPS
0.6Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated broad-based, high-quality growth: double-digit sales growth, significant margin expansion, strong EPS and cash generation, record category and regional performance, and upgraded full-year guidance. Management outlined clear growth levers for Artegraft and RFA, active M&A pursuit, and operational investments, while acknowledging near-term execution and regulatory timing risks (distribution lumpiness, slower patches growth, RFA rollout complexities, and potential supply chain impacts). On balance, positive financial momentum and upgraded guidance outweigh the identified operational and regulatory headwinds.Company Guidance
Revenue and Growth
Q1 sales grew 11% year-over-year; organic sales growth of 10% (8% ASP increase, 2% unit growth). Direct sales grew 12.8% organically (8.4% price, 4.4% units) excluding distribution.
Strong Profitability and Margins
Gross margin of 72.7% in Q1, a 350 basis-point improvement versus prior year driven by higher ASPs, positive mix and manufacturing efficiencies; operating income rose 41% to $17.8M and operating margin improved to 27% (vs. 21% prior year).
Earnings Per Share and Cash Generation
Fully diluted EPS of $0.68, up 42% year-over-year. Cash from operations of $15.1M (vs. $9M prior year); ended Q1 with $367M in cash and securities (increase of $8M) and paid $5.7M in dividends.
Product Category Outperformance
Record sales in key categories: grafts up 20%, valvulotomes up 15%, carotid shunts up 11%, each posting record sales in Q1.
Geographic Strength and Expansion
All three regions posted record sales: EMEA +20%, APAC +18%, Americas +7%. Company increased direct presence (Poland planned Q4) and sales headcount: 158 reps (up 3% YoY) and 35 RSMs/country managers (up 13% YoY).
Artegraft Momentum and Guidance
Worldwide Artegraft sales grew 36% in Q1; international Artegraft sales were $2.1M in Q1. Company expects 2026 Artegraft sales of $10M vs $4M in 2025 (projected +150%). Health Canada approval secured with H2 2026 launch planned.
RestoreFlow Allograft (RFA) Expansion
RFA grew 25% in Q1. German implants expected to begin in Q2; Irish approval and Irish warehouse audit expected in H2 enabling local distribution; filings planned in Australia and several European countries in 2026.
Upgraded Full-Year Guidance
Affirmed 2026 revenue guidance of $280M (~12% organic growth) and increased annual guidance: gross margin to 72.3%, operating income to $79.8M (~24% growth vs adjusted 2025), and adjusted diluted EPS to $3 (approx. 26% growth). Q2 revenue guided to $71.5M and operating margin to 30%.
Operational Efficiency Gains
Manufacturing and operational efficiencies (automation, lean/Kaizen) contributed to margin expansion; direct labor reduced from 211 (end 2023) to 175 (end 2025) while device output rose.
Active M&A and Strategic Playbook
Management is actively pursuing acquisitions (2–3 term sheets year-to-date) targeting niche open vascular and cardiac surgery products in the $15M–$150M revenue range, while maintaining a playbook focused on product quality, direct expansion, and profitability.
LMAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LMAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $111.72 | $109.95 | -1.59% |
Feb 25, 2026 | $90.94 | $113.15 | +24.42% |
Nov 06, 2025 | $85.00 | $86.21 | +1.43% |
Aug 05, 2025 | $84.82 | $92.38 | +8.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lemaitre Vascular (LMAT) report earnings?
Lemaitre Vascular (LMAT) is schdueled to report earning on Jul 23, 2026, After Close (Confirmed).
What is Lemaitre Vascular (LMAT) earnings time?
Lemaitre Vascular (LMAT) earnings time is at Jul 23, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LMAT EPS forecast?
LMAT EPS forecast for the fiscal quarter 2026 (Q2) is 0.81.